Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03951415 |
|
Recruitment Status : Unknown
Verified March 2021 by J.R. Kroep, Leiden University Medical Center.
Recruitment status was: Active, not recruiting
First Posted : May 15, 2019
Last Update Posted : April 1, 2021
|
Sponsor:
Leiden University Medical Center
Collaborators:
Amsterdam University Medical Center
Erasmus Medical Center
Maastricht University Medical Center
The Netherlands Cancer Institute
Radboud University Medical Center
University Medical Center Groningen
UMC Utrecht
AstraZeneca
Information provided by (Responsible Party):
J.R. Kroep, Leiden University Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | August 1, 2021 |
| Estimated Study Completion Date : | August 1, 2021 |